CARLSBAD, Calif., April 4, 2011 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) today announced the launch of its TaqMan® Mutation Detection Assays -- highly sensitive and novel molecular analysis research tools with the precision to detect a single mutant molecule hiding in a background of 1 million normal copies.
Developed for clinical researchers to validate and screen for extremely minute levels of mutations in cancer-related genes, the TaqMan® Mutation Detection Assaysare unparalleled in the market showing at least 10-fold greater sensitivity than currently available products.
"Employing TaqMan® Mutation Detection Assays in our work has enabled us to detect cancer-relevant DNA mutations more robustly even within abundant backgrounds of normal material," said Pierre Puig-Laurent, Ph.D., Professor at Descartes University Medical School in Paris, who is also responsible for the Clinical Oncogenetic Unit in the Department of Genetics at the European Georges Pompidou Hospital Paris, and Director of UMR-S775 INSERM laboratory. "The level of sensitivity that can be achieved with this new technique is superior to classical methods we have tested and lends itself well to clinical research applications, including the initial identification of mutations," he said.
The assays will also support the development of emerging technologies and future products for detecting circulating tumor cells (CTCs), which scientists in the United Kingdom recently said could help determine aggressiveness levels and potential treatments for the disease, as reported by Reuters last week.
TaqMan® Mutation Detection Assays, available as part of an early release program with a full launch in July,focus on detecting mutations in three human genes associated with colorectal, lung, pancreatic and breast cancer -- the most common and deadliest forms of the disease that last year accounted for about 540,000 new cases in the United States alone. The genes -- KRAS, BRAF and EGFR – have also been implicated in leukemia, non-Hodgkin's lymphoma, melanoma and papillary thyroid carcinoma. Life Technologies is planning to expand its portfolio of cancer research assays to cover many other cancer-related genes.
Cancer begins at the genetic level, where elements from the environment -- ultraviolet rays, carcinogens, or toxins in the food supply – can cause a series of mutations to specific genes that, when not addressed by the cellular repair mechanism, can lead to uncontrolled cell division, the hallmark of the disease. There were 1.2 million new cases of cancer last year in the U.S., and the 12 most common forms of the disease claimed more than 400,000 Americans in 2010, or about 1,100 per day, according to the National Cancer Institute.
TaqMan® Mutation Detection Assaysare powered by castPCR (competitive allele-specific TaqMan® polymerase chain reaction), a novel technology that utilizes a combination of proprietary assay design as well as chemistry to amplify mutations of interest and suppression factors to silence other DNA molecules in samples. Coupled with Life Technologies' gold standard TaqMan® brand of molecular probes and primers, the Mutation Detection Assays enable a level of sensitivity and specificity that are unmatched in the industry.
"Cancer researchers can now essentially find that proverbial needle in a haystack," said Sam Raha, Vice President & General Manager of NextGen qPCR & Content for Life Technologies. "As translational research tools, they could support future drug development and better clinical trial designs for evaluating biomarker-based treatments."
CastPCR has been optimized for use on standard qPCR instrumentation such as Life Technologies' ViiA™ 7 Real-Time PCR System. Life Technologies' new data analysis software tool, which will be available for the full launch in July 2011, coupled with the validated assays and instruments provide a complete workflow solution for cancer researchers.
The ViiA™ 7 Real-Time PCR System and TaqMan® Mutation Detection Assays are for research use only, and not for use in diagnostic procedures.
Life Technologies and Dr. Puig will host poster sessions on castPCR (8 a.m.-noon, April 5, 2011; Abstract Nos. 3066 & 3071) at the American Association of Cancer Research conference taking place April 2-6, 2011 at the Orlando Convention Center in Orlando, Fla. More information on the TaqMan® Mutation Detection Assays will also be available at the Life Technologies booth (#1411).
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific and medical advancements that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance the fields of discovery and translational research, molecular medicine, stem cell-based therapies, food safety and animal health, and 21st century forensics. The company manufactures both molecular diagnostic and research use only products. Life Technologies' industry-leading brands are found in nearly every life sciences lab in the world and include innovative instrument systems under the Applied Biosystems and Ion Torrent names, as well as, the broadest range of reagents with its Invitrogen, GIBCO, Ambion, Molecular Probes and TaqMan® products. Life Technologies had sales of $3.6 billion in 2010, has a workforce of approximately 11,000 people, has a presence in approximately 160 countries, and possesses one of the largest intellectual property estates in the life sciences industry, with approximately 3,900 patents and exclusive licenses. For more information on how we are making a difference, please visit our website: http://www.lifetechnologies.com.
Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.